HRT After 50: What the Evidence Actually Shows (A Calm, Complete Guide)
In 2002, a large American study called the Women's Health Initiative published interim results suggesting that hormone replacement therapy significantly increased the risk of breast cancer, heart disease, and stroke. Within months, HRT prescriptions plummeted across the Western world. A generation of women stopped taking it. A generation of GPs became reluctant to prescribe it. Many women went through the menopause transition without support they could have had.
In the decades since, that study has been substantially re-evaluated. Methodological problems have been identified. Subsequent analyses have produced different conclusions. New research has added considerably to the picture. The current evidence on HRT — its benefits, its risks, and for whom it's appropriate — is substantially different from what the 2002 panic left behind.
This article presents the current evidence clearly. Not to advocate for HRT or against it — the decision is individual and requires a conversation with a doctor who knows your medical history. But to ensure that the decision, if you face it, is made with accurate information rather than two-decade-old fear.
Most women's HRT decisions are still being made on the basis of a 2002 study that has since been significantly revised. The current evidence is more nuanced, and more reassuring, than the cultural memory of that study suggests.
The 2002 WHI study — and why it changed the picture
The Women's Health Initiative was a large, randomised controlled trial that enrolled over 160,000 postmenopausal American women. The arm studying combined estrogen and progestogen HRT was stopped early in 2002 when interim results showed increased rates of breast cancer, heart disease, stroke, and blood clots compared to placebo.
The study was reported as definitive. It wasn't. Several significant methodological problems have since been identified:
The average age of participants was 63 — significantly older than the women most likely to use HRT for menopause symptoms, who are typically in their late 40s to mid 50s. Starting HRT a decade after menopause produces different results from starting it during or shortly after the transition — a distinction now known as the 'timing hypothesis' or 'window of opportunity.'
The study used only oral conjugated equine estrogen (derived from horse urine) and medroxyprogesterone acetate — a synthetic progestogen. Most current HRT uses different forms and routes of administration with different risk profiles. The blood clot and stroke risks, in particular, appear to be route-dependent: oral estrogen has higher clotting risk than transdermal estrogen (patches, gels, sprays).
The absolute risk increases were small even in the original study, though the relative risk language used in reporting made them sound larger. The absolute increase in breast cancer in the combined HRT arm was approximately 8 additional cases per 10,000 women per year of use — a figure that requires context.
Since 2002, multiple large observational studies, re-analyses of the WHI data, and newer randomised trials have refined the picture significantly. The current NICE guideline on menopause (NG23, last updated 2019 and under ongoing review) and the British Menopause Society position statements reflect a substantially more nuanced evidence base.
What HRT is — the forms and routes
The hormones
Estrogen is the primary hormone in HRT — it is responsible for most of the symptom-relieving effects. Women who have not had a hysterectomy must take progesterone (or a progestogen) alongside estrogen to protect the endometrium from the cell proliferation that unopposed estrogen produces.
Progesterone (body-identical micronised progesterone, such as Utrogestan) and synthetic progestogens (such as norethisterone, levonorgestrel, medroxyprogesterone acetate) have different safety profiles. The current evidence suggests that body-identical micronised progesterone may have a lower breast cancer risk than older synthetic progestogens — a distinction that matters for individual treatment decisions.
Testosterone: the role of testosterone in women's health is increasingly recognised. Low testosterone after menopause contributes to low libido, low mood, and fatigue. Testosterone replacement is not universally prescribed in the UK but is available for women with documented deficiency and can make a significant difference to quality of life in appropriate candidates.
The routes of administration
Route matters — particularly for the risk of blood clots and stroke, which are primarily associated with oral (tablet) estrogen passing through the liver:
Transdermal estrogen (patches, gels, sprays, implants): absorbed through the skin, bypassing the liver. The blood clot and stroke risk associated with transdermal estrogen appears to be no higher than background population risk — a significant safety distinction from oral estrogen. Current NICE guidance indicates transdermal estrogen does not increase the risk of venous thromboembolism (VTE).
Oral estrogen (tablets): effective but carries higher VTE and stroke risk than transdermal forms, particularly for women with existing cardiovascular risk factors or a personal or family history of blood clots.
Local (vaginal) estrogen: very low-dose estrogen applied directly to vaginal tissues. Addresses genitourinary symptoms without systemic absorption. Not the same as systemic HRT and has a different — and substantially more reassuring — safety profile.
The benefits — with current evidence level
Vasomotor symptom relief
HRT is the most effective treatment available for hot flushes and night sweats — more effective than any other medical or lifestyle intervention. The evidence is robust and consistent. For women with moderate to severe vasomotor symptoms significantly affecting quality of life, HRT is the first-line treatment recommended by NICE, the British Menopause Society, and most major menopause organisations.
Bone protection
Estrogen is central to bone maintenance. Its decline in menopause accelerates bone loss, increasing fracture risk. HRT taken during and after menopause maintains bone density and reduces fracture risk — particularly important for women at high risk of osteoporosis or with early menopause. The effect on bone is covered alongside lifestyle approaches in our article on protecting bones after 50.
Cardiovascular protection — the timing question
This is where the timing hypothesis matters most. The WHI study found increased cardiovascular risk in women who started HRT at average age 63, years after menopause. Subsequent analysis and other research suggests that starting HRT within ten years of menopause (or under age 60) — the 'window of opportunity' — may have a neutral or even protective cardiovascular effect. Starting HRT after 60 or more than ten years after menopause appears to carry higher cardiovascular risk.
This distinction is now incorporated into NICE guidance and BMS recommendations: HRT is not routinely recommended primarily for cardiovascular protection, but for women using it for symptom relief who are within the appropriate timing window, cardiovascular risk is not increased and may be reduced.
Cognitive and mental health effects
The evidence here is emerging and complex. Some studies suggest HRT started in perimenopause may have cognitive protective effects and may reduce dementia risk when started in the timing window. Other studies are more equivocal. Current guidance does not recommend HRT specifically for cognitive protection, but it should not be withheld from women using it for other reasons on the basis of cognitive risk — the evidence does not support cognitive harm from appropriately timed HRT.
The mental health effects of HRT are more established at the symptom level: estrogen has direct effects on serotonin, GABA, and dopamine, and HRT relieves the perimenopausal anxiety, mood fluctuation, and emotional lability that are hormonally driven in many women — effects that antidepressants and anxiolytics alone do not address when the underlying cause is hormonal.
Quality of life and sexual health
HRT, including vaginal estrogen, significantly improves the genitourinary symptoms — vaginal dryness, pain during sex, recurrent UTIs, urinary urgency — that are among the most quality-of-life-affecting and least discussed consequences of estrogen loss. These are covered in detail in our article on vaginal dryness and urogenital changes after menopause.
The risks — with current evidence level
Breast cancer — the most important and most misunderstood risk
The breast cancer risk associated with HRT is the primary concern for most women and requires careful, specific communication:
Combined HRT (estrogen plus progestogen) is associated with a small increase in breast cancer risk. The magnitude of this increase depends on the type of progestogen used and the duration of use. The current evidence suggests that body-identical micronised progesterone (Utrogestan) may have a lower breast cancer risk than older synthetic progestogens.
Estrogen-only HRT (used only by women who have had a hysterectomy) does not appear to increase breast cancer risk and in some analyses appears to decrease it.
To put the absolute risk in context: five years of combined HRT is associated with approximately 5 additional breast cancer cases per 1,000 women — a risk smaller than that associated with drinking two units of alcohol daily, or with obesity. This is not an argument to dismiss the risk — it is an argument to present it accurately, in context, so that individual women can weigh it against the quality of life impact of their symptoms.
Blood clots (VTE)
Oral estrogen increases VTE risk. Transdermal estrogen does not appear to increase VTE risk above background. For women with risk factors for blood clots — personal history, family history, obesity, prolonged immobility — transdermal forms are strongly preferred.
Stroke
Oral estrogen is associated with a small increase in stroke risk. Transdermal estrogen does not appear to increase stroke risk. Women with migraine with aura are at higher baseline stroke risk and should use transdermal estrogen rather than oral.
The risk picture for HRT is route-dependent, dose-dependent, hormone-type-dependent, and timing-dependent. A blanket statement that 'HRT is dangerous' or 'HRT is safe' is equally inaccurate. Individual assessment by a clinician who knows your history is the appropriate response.
Who HRT is suitable for
Current NICE guidance supports HRT for women experiencing menopause symptoms that affect quality of life, after an informed discussion of the benefits and risks in their individual context. The guidance explicitly states that for most women under 60, the benefits of HRT outweigh the risks.
Women for whom HRT is generally considered appropriate include: those with moderate to severe vasomotor symptoms; those with confirmed premature ovarian insufficiency (before age 40), for whom HRT is strongly recommended until average age of natural menopause; those at high risk of osteoporosis; and those whose quality of life is significantly affected by menopause symptoms.
Who should discuss HRT carefully with a specialist
HRT is not universally suitable and certain personal histories require specialist discussion rather than routine GP prescribing. These include: personal history of estrogen-receptor positive breast cancer (though even here, local vaginal estrogen may be appropriate); undiagnosed vaginal bleeding; active liver disease; and certain blood clotting disorders. These are not absolute rules — the conversation with a menopause specialist is necessary to weigh individual circumstances.
How to have the conversation with your GP
Many women are still not having adequate conversations about HRT because they assume their GP will advise against it, or because previous consultations left them with the impression that HRT is too risky to consider. The current evidence does not support that position for most women under 60 experiencing significant symptoms.
If you want to discuss HRT with your GP: bring a clear description of your symptoms, how long you've had them, and how they affect your quality of life. Ask specifically about transdermal estrogen and body-identical micronised progesterone, which have more favourable risk profiles than older formulations. If you feel your symptoms are being dismissed or your request not adequately considered, you have the right to ask for referral to a menopause specialist.
The British Menopause Society's 'Find a Menopause Specialist' tool lists registered specialists. The Menopause Charity provides resources including a GP training programme and advocacy tools. The 'Newson Health' and 'balance' app (developed by Dr Louise Newson) provides symptom tracking and information.
HRT is not the right decision for every woman, and it is not the only option for managing the menopause transition. But for women with significant symptoms affecting quality of life, it is a legitimate, evidence-supported option that deserves to be considered with accurate information — not with the residual fear of a 2002 study that has since been substantially revised.
The Menopause Hub at femmementor.com/menopause-hub brings together all menopause content on this site — from the perimenopause guide to symptom management to medical options.
